Literature DB >> 24993473

Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy.

Veena Rao1, Eric Schneider1, Alan D Proia2, Sharon Fekrat1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24993473     DOI： 10.1001/jamaophthalmol.2014.1088

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN： 2168-6165            Impact factor:   7.389


× No keyword cloud information.
  4 in total

Review 1.  Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review.

Authors:  Shruthi Harish Bindiganavile; Nita Bhat; Andrew G Lee; Dan S Gombos; Nagham Al-Zubidi
Journal:  J Immunother Precis Oncol       Date:  2021-02-25

Review 2.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

Review 3.  Ocular Toxicity of Targeted Anticancer Agents.

Authors:  Blake H Fortes; Prashant D Tailor; Lauren A Dalvin
Journal:  Drugs       Date:  2021-03-31       Impact factor: 9.546

4.  Erlotinib-associated severe bilateral recalcitrant keratouveitis after corneal EDTA chelation.

Authors:  Zimei Zhou; Kumar Sambhav; K V Chalam
Journal:  Am J Ophthalmol Case Rep       Date:  2016-06-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.